Liver Cancer - Pipeline Review, H1 2016

Description:
Liver Cancer - Pipeline Review, H1 2016

Summary

‘Liver Cancer - Pipeline Review, H1 2016’, provides an overview of the Liver Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Liver Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Liver Cancer and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real-time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision-making capabilities and helps to create effective counter-strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Liver Cancer
- The report reviews pipeline therapeutics for Liver Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Liver Cancer therapeutics and enlists all their major and minor projects
- The report assesses Liver Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Liver Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Liver Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Liver Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Contents:

Introduction
Liver Cancer Overview
Therapeutics Development
Liver Cancer - Therapeutics under Development by Companies
Liver Cancer - Therapeutics under Investigation by Universities/Institutes
Liver Cancer - Pipeline Products Glance
Liver Cancer - Products under Development by Companies
Liver Cancer - Products under Investigation by Universities/Institutes
Liver Cancer - Companies Involved in Therapeutics Development
Liver Cancer - Therapeutics Assessment
Drug Profiles
Liver Cancer - Dormant Projects
Liver Cancer - Discontinued Products
Liver Cancer - Product Development Milestones
Appendix
List of Tables
Number of Products under Development for Liver Cancer, H1 2016
Number of Products under Development for Liver Cancer - Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Number of Products under Development by Companies, H1 2016 (Contd..1)
Number of Products under Development by Companies, H1 2016 (Contd..2)
Number of Products under Development by Companies, H1 2016 (Contd..3)
Number of Products under Development by Companies, H1 2016 (Contd..4)
Number of Products under Development by Companies, H1 2016 (Contd..5)
Number of Products under Development by Companies, H1 2016 (Contd..6)
Number of Products under Development by Companies, H1 2016 (Contd..7)
Number of Products under Development by Companies, H1 2016 (Contd..8)
Number of Products under Development by Companies, H1 2016 (Contd..9)
Number of Products under Development by Companies, H1 2016 (Contd..10)
Number of Products under Development by Companies, H1 2016 (Contd..11)
Number of Products under Development by Companies, H1 2016 (Contd..12)
Number of Products under Investigation by Universities/Institutes, H1 2016
Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Development, H1 2016
Products under Development by Companies, H1 2016
Products under Development by Companies, H1 2016 (Contd..1)
Products under Development by Companies, H1 2016 (Contd..2)
Products under Development by Companies, H1 2016 (Contd..3)
Products under Development by Companies, H1 2016 (Contd..4)
Products under Development by Companies, H1 2016 (Contd..5)
Products under Development by Companies, H1 2016 (Contd..6)
Products under Development by Companies, H1 2016 (Contd..7)
Products under Development by Companies, H1 2016 (Contd..8)
Products under Development by Companies, H1 2016 (Contd..9)
Products under Development by Companies, H1 2016 (Contd..10)
Products under Development by Companies, H1 2016 (Contd..11)
Products under Development by Companies, H1 2016 (Contd..12)
Products under Development by Companies, H1 2016 (Contd..13)
Products under Development by Companies, H1 2016 (Contd..14)
Products under Development by Companies, H1 2016 (Contd..15)
Products under Development by Companies, H1 2016 (Contd..16)
Products under Development by Companies, H1 2016 (Contd..17)
Products under Development by Companies, H1 2016 (Contd..18)
Products under Investigation by Universities/Institutes, H1 2016
Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2016 (Contd..2)
Liver Cancer - Pipeline by 4SC AG, H1 2016
Liver Cancer - Pipeline by AB Science SA, H1 2016
Liver Cancer - Pipeline by Acceleron Pharma, Inc., H1 2016
Liver Cancer - Pipeline by ACROVIS Pharma AG, H1 2016
Liver Cancer - Pipeline by Adaptimmune Therapeutics Plc, H1 2016
Liver Cancer - Pipeline by Aduro BioTech, Inc., H1 2016
Liver Cancer - Pipeline by Advanced Accelerator Applications S.A., H1 2016
Liver Cancer - Pipeline by Advosten Laboratories, LLC, H1 2016
Liver Cancer - Pipeline by Alfact Innovation, H1 2016
Liver Cancer - Pipeline by Alnylam Pharmaceuticals, Inc., H1 2016
Liver Cancer - Pipeline by American Gene Technologies International Inc., H1 2016
Liver Cancer - Pipeline by Amgen Inc., H1 2016
Liver Cancer - Pipeline by AndroScience Corporation, H1 2016
Liver Cancer - Pipeline by APAvadis Biotechnologies Srl, H1 2016
Liver Cancer - Pipeline by Arbutus Biopharma Corporation, H1 2016
Liver Cancer - Pipeline by ArQule, Inc., H1 2016
Liver Cancer - Pipeline by Array BioPharma Inc., H1 2016
Liver Cancer - Pipeline by Arrowhead Pharmaceuticals, Inc., H1 2016
Liver Cancer - Pipeline by Astex Pharmaceuticals, Inc., H1 2016
Liver Cancer - Pipeline by AstraZeneca Plc, H1 2016
Liver Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H1 2016
Liver Cancer - Pipeline by Bayer AG, H1 2016
Liver Cancer - Pipeline by Beijing Kawin Technology Share-Holding Co., Ltd., H1 2016
Liver Cancer - Pipeline by Betta Pharmaceuticals Co. Ltd., H1 2016
Liver Cancer - Pipeline by Bio-Cancer Treatment International Limited, H1 2016
Liver Cancer - Pipeline by BioCancell Ltd, H1 2016
Liver Cancer - Pipeline by Biogazelle, H1 2016
Liver Cancer - Pipeline by Biomics Biotechnologies Co., Ltd., H1 2016
Liver Cancer - Pipeline by BioStar Corporation, H1 2016
Liver Cancer - Pipeline by BioStar Pharmaceuticals, Inc., H1 2016
Liver Cancer - Pipeline by Blueprint Medicines Corporation, H1 2016
Liver Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2016
Liver Cancer - Pipeline by Boston Biomedical, Inc., H1 2016
Liver Cancer - Pipeline by Can-Fite BioPharma Ltd., H1 2016
Liver Cancer - Pipeline by CASI Pharmaceuticals Inc., H1 2016
Liver Cancer - Pipeline by CCRP Therapeutics GmbH, H1 2016
Liver Cancer - Pipeline by Celgene Corporation, H1 2016
Liver Cancer - Pipeline by Celldex Therapeutics, Inc., H1 2016
Liver Cancer - Pipeline by Celprogen, Inc., H1 2016
Liver Cancer - Pipeline by Celsion Corporation, H1 2016
Liver Cancer - Pipeline by China Medical System Holdings Limited, H1 2016
Liver Cancer - Pipeline by Chiome Bioscience, Inc., H1 2016
Liver Cancer - Pipeline by Chipscreen Biosciences Ltd, H1 2016
Liver Cancer - Pipeline by Chroma Therapeutics Limited, H1 2016
Liver Cancer - Pipeline by CohBar, Inc., H1 2016
Liver Cancer - Pipeline by CytRx Corporation, H1 2016
Liver Cancer - Pipeline by CZ BioMed Corp, H1 2016
Liver Cancer - Pipeline by Daichi Sankyo Company, Limited, H1 2016
Liver Cancer - Pipeline by Delcath Systems, Inc., H1 2016
Liver Cancer - Pipeline by Dicerna Pharmaceuticals, Inc., H1 2016
Liver Cancer - Pipeline by Digna Biotech, S.L., H1 2016
Liver Cancer - Pipeline by Double Bond Pharmaceutical International AB, H1 2016
Liver Cancer - Pipeline by Eisai Co., Ltd., H1 2016
Liver Cancer - Pipeline by Eli Lilly and Company, H1 2016
Liver Cancer - Pipeline by Endocyte, Inc., H1 2016
Liver Cancer - Pipeline by eTheRNA Immunotherapies NV, H1 2016
Liver Cancer - Pipeline by Eureka Therapeutics, Inc., H1 2016
Liver Cancer - Pipeline by Exelixis, Inc., H1 2016
Liver Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
Liver Cancer - Pipeline by Genelux Corporation, H1 2016
Liver Cancer - Pipeline by Genoscience Pharma, H1 2016
Liver Cancer - Pipeline by Genosco, H1 2016
Liver Cancer - Pipeline by GenSpera, Inc., H1 2016
Liver Cancer - Pipeline by GlaxoSmithKline Plc, H1 2016
Liver Cancer - Pipeline by Golden Biotechnology Corp., H1 2016
Liver Cancer - Pipeline by Green Cross Cell Corporation, H1 2016
Liver Cancer - Pipeline by H3 Biomedicine Inc., H1 2016
Liver Cancer - Pipeline by HanAll Biopharma Co., Ltd., H1 2016
Liver Cancer - Pipeline by HEC Pharm Co., Ltd., H1 2016
Liver Cancer - Pipeline by HitGen LTD, H1 2016
Liver Cancer - Pipeline by Horizon Pharma Plc, H1 2016
Liver Cancer - Pipeline by Huperion Sarl, H1 2016
Liver Cancer - Pipeline by Immunencum AB, H1 2016
Liver Cancer - Pipeline by Immunitor, Inc., H1 2016
Liver Cancer - Pipeline by Immunomedics, Inc., H1 2016
Liver Cancer - Pipeline by Immunovative Therapies, Ltd., H1 2016
Liver Cancer - Pipeline by IMPACT Therapeutics, Inc., H1 2016
Liver Cancer - Pipeline by In-Cell-Art S.A.S., H1 2016
Liver Cancer - Pipeline by Incanthera Ltd., H1 2016
Liver Cancer - Pipeline by Incuron, LLC, H1 2016
Liver Cancer - Pipeline by InteRNA Technologies B.V., H1 2016
Liver Cancer - Pipeline by Jasco Pharmaceuticals, LLC., H1 2016
Liver Cancer - Pipeline by Jenrin Discovery, Inc., H1 2016
Liver Cancer - Pipeline by Johnson & Johnson, H1 2016
Liver Cancer - Pipeline by JW Pharmaceutical Corporation, H1 2016
Liver Cancer - Pipeline by KAHR medical Ltd., H1 2016
Liver Cancer - Pipeline by Karcinolys SAS, H1 2016
Liver Cancer - Pipeline by Keystone Nano, Inc., H1 2016
Liver Cancer - Pipeline by Kite Pharma, Inc., H1 2016
Liver Cancer - Pipeline by Komipharm International Co., Ltd., H1 2016
Liver Cancer - Pipeline by Kowa Company, Ltd., H1 2016
Liver Cancer - Pipeline by Les Laboratoires Servier SAS, H1 2016
Liver Cancer - Pipeline by Ligand Pharmaceuticals, Inc., H1 2016
Liver Cancer - Pipeline by Lixte Biotechnology Holdings, Inc., H1 2016
Liver Cancer - Pipeline by Lytix Biopharma AS, H1 2016
Liver Cancer - Pipeline by MaxCyte, Inc., H1 2016
Liver Cancer - Pipeline by MedImmune, LLC, H1 2016
Liver Cancer - Pipeline by Medivation, Inc., H1 2016
Liver Cancer - Pipeline by Medivir AB, H1 2016
Liver Cancer - Pipeline by Merck & Co., Inc., H1 2016
Liver Cancer - Pipeline by Merck KGaA, H1 2016
Liver Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2016
Liver Cancer - Pipeline by Midatech Pharma Plc, H1 2016
Liver Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016
Liver Cancer - Pipeline by Mirna Therapeutics, Inc., H1 2016
Liver Cancer - Pipeline by Molecular Partners AG, H1 2016
Liver Cancer - Pipeline by MultiCell Technologies, Inc., H1 2016
Liver Cancer - Pipeline by Nimbus Therapeutics, LLC, H1 2016
Liver Cancer - Pipeline by NormOxys, Inc., H1 2016
Liver Cancer - Pipeline by Northwest Biotherapeutics, Inc., H1 2016
Liver Cancer - Pipeline by Novartis AG, H1 2016
Liver Cancer - Pipeline by NovaTarg Therapeutics, Inc, H1 2016
Liver Cancer - Pipeline by Nymox Pharmaceutical Corporation, H1 2016
Liver Cancer - Pipeline by Omeros Corporation, H1 2016
Liver Cancer - Pipeline by Omnitura Therapeutics Inc., H1 2016
Liver Cancer - Pipeline by Oncolys BioPharma Inc., H1 2016
Liver Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H1 2016
Liver Cancer - Pipeline by OncoTherapy Science, Inc., H1 2016
Liver Cancer - Pipeline by Oneness Biotech Co., Ltd., H1 2016
Liver Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016
Liver Cancer - Pipeline by Onxeo SA, H1 2016
Liver Cancer - Pipeline by OPKO Health, Inc., H1 2016
Liver Cancer - Pipeline by Oribase Pharma, H1 2016
Liver Cancer - Pipeline by Otsuka Holdings Co., Ltd., H1 2016
Liver Cancer - Pipeline by Panacea Pharmaceuticals, Inc., H1 2016
Liver Cancer - Pipeline by Peptinov SAS, H1 2016
Liver Cancer - Pipeline by Pfizer Inc., H1 2016
Liver Cancer - Pipeline by Pharma Mar, S.A., H1 2016
Liver Cancer - Pipeline by PharmAbcine, Inc., H1 2016
Liver Cancer - Pipeline by PharmaEssentia Corporation, H1 2016
Liver Cancer - Pipeline by Phosplatin Therapeutics LLC, H1 2016
Liver Cancer - Pipeline by Polaris Pharmaceuticals, Inc., H1 2016
Liver Cancer - Pipeline by Progen Pharmaceuticals Limited, H1 2016
Liver Cancer - Pipeline by ProMetic Life Sciences Inc., H1 2016
Liver Cancer - Pipeline by Provecs Medical GmbH, H1 2016
Liver Cancer - Pipeline by Provectus Biopharmaceuticals, Inc., H1 2016
Liver Cancer - Pipeline by Quimatrixx, S.L., H1 2016
Liver Cancer - Pipeline by Raptor Pharmaceutical Corp., H1 2016
Liver Cancer - Pipeline by RedHill Biopharma Ltd., H1 2016
Liver Cancer - Pipeline by Regen BioPharma, Inc., H1 2016
Liver Cancer - Pipeline by Regulus Therapeutics Inc., H1 2016
Liver Cancer - Pipeline by Rigontec GmbH, H1 2016
Liver Cancer - Pipeline by Saronic Biotechnology, Inc., H1 2016
Liver Cancer - Pipeline by Savoy Pharmaceuticals, Inc., H1 2016
Liver Cancer - Pipeline by Shenogen Pharma Group Ltd., H1 2016
Liver Cancer - Pipeline by Shenzen SiBiono GeneTech Co., Ltd., H1 2016
Liver Cancer - Pipeline by Silence Therapeutics Plc, H1 2016
Liver Cancer - Pipeline by Sillajen Biotherapeutics, H1 2016
Liver Cancer - Pipeline by Simcere Pharmaceutical Group, H1 2016
Liver Cancer - Pipeline by Synovo GmbH, H1 2016
Liver Cancer - Pipeline by Taiwan Liposome Company, Ltd., H1 2016
Liver Cancer - Pipeline by Tara Immuno-Oncology Therapeutics LLC, H1 2016
Liver Cancer - Pipeline by Targetome, H1 2016
Liver Cancer - Pipeline by Therapure Biopharma Inc., H1 2016
Liver Cancer - Pipeline by Theravectys SA, H1 2016
Liver Cancer - Pipeline by Tiziana Life Sciences Plc, H1 2016
Liver Cancer - Pipeline by Toko Pharmaceutical Industries Co., Ltd., H1 2016
Liver Cancer - Pipeline by TRACON Pharmaceuticals, Inc., H1 2016
Liver Cancer - Pipeline by Transgene Biotek Limited, H1 2016
Liver Cancer - Pipeline by Tumorend, LLC, H1 2016
Liver Cancer - Pipeline by UbiVac, LLC, H1 2016
Liver Cancer - Pipeline by VasGene Therapeutics, Inc., H1 2016
Liver Cancer - Pipeline by Vaxon Biotech, H1 2016
Liver Cancer - Pipeline by Vect-Horus S.A.S., H1 2016
Liver Cancer - Pipeline by Verlyx Pharma Inc., H1 2016
Liver Cancer - Pipeline by VG Life Sciences, Inc., H1 2016
Liver Cancer - Pipeline by Vicus Therapeutics, LLC, H1 2016
Liver Cancer - Pipeline by Virttu Biologics Limited, H1 2016
Liver Cancer - Pipeline by Vyriad, H1 2016
Assessment by Monotherapy Products, H1 2016
Assessment by Combination Products, H1 2016
Number of Products by Stage and Target, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Liver Cancer - Dormant Projects, H1 2016
Liver Cancer - Dormant Projects (Contd..1), H1 2016
Liver Cancer - Dormant Projects (Contd..2), H1 2016
Liver Cancer - Dormant Projects (Contd..3), H1 2016
Liver Cancer - Dormant Projects (Contd..4), H1 2016
Liver Cancer - Dormant Projects (Contd..5), H1 2016
Liver Cancer - Dormant Projects (Contd..6), H1 2016
Liver Cancer - Dormant Projects (Contd..7), H1 2016
Liver Cancer - Dormant Projects (Contd..8), H1 2016
Liver Cancer - Dormant Projects (Contd..9), H1 2016
Liver Cancer - Dormant Projects (Contd..10), H1 2016
Liver Cancer - Dormant Projects (Contd..11), H1 2016
Liver Cancer - Dormant Projects (Contd..12), H1 2016
Liver Cancer - Dormant Projects (Contd..13), H1 2016
Liver Cancer - Dormant Projects (Contd..14), H1 2016
Liver Cancer - Dormant Projects (Contd..15), H1 2016
Liver Cancer - Dormant Projects (Contd..16), H1 2016
Liver Cancer - Dormant Projects (Contd..17), H1 2016
Liver Cancer - Discontinued Products, H1 2016
Liver Cancer - Discontinued Products (Contd..1), H1 2016
Liver Cancer - Discontinued Products (Contd..2), H1 2016
Liver Cancer - Discontinued Products (Contd..3), H1 2016

List of Figures

Number of Products under Development for Liver Cancer, H1 2016
Number of Products under Development for Liver Cancer - Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Number of Products under Investigation by Universities/Institutes, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy Products, H1 2016
Assessment by Combination Products, H1 2016
Number of Products by Top 10 Targets, H1 2016
Number of Products by Stage and Top 10 Targets, H1 2016
Number of Products by Top 10 Mechanism of Actions, H1 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
Number of Products by Top 10 Routes of Administration, H1 2016
Number of Products by Stage and Top 10 Routes of Administration, H1 2016
Number of Products by Top 10 Molecule Types, H1 2016
Number of Products by Stage and Top 10 Molecule Types, H1 2016

Ordering:
Order Online - http://www.researchandmarkets.com/reports/3783300/
Order by Fax - using the form below
Order by Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Liver Cancer - Pipeline Review, H1 2016
Web Address: http://www.researchandmarkets.com/reports/3783300/
Office Code: SC

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Product Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td>□</td>
<td>USD 2500</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td>□</td>
<td>USD 5000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td>□</td>
<td>USD 7500</td>
</tr>
</tbody>
</table>

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: □ Mr □ Mrs □ Dr □ Miss □ Ms □ Prof
First Name: ____________________________ Last Name: ________________________
Email Address: *
Job Title: _________________________________________________________________
Organisation: ______________________________________________________________
Address: _________________________________________________________________
City: _________________________________________________________________
Postal / Zip Code: ___________________________________________________________
Country: _________________________________________________________________
Phone Number: ____________________________________________________________
Fax Number: _____________________________________________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB9853083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: _______________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:

(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World